Recombinant SLPI, when administered in an aerosolised form to CF patients, can suppress airway NE levels and reduce levels of the neutrophil chemokine interleukin-8 (IL-8) in BALF obtained from these patients [16,17]. Here, CXCL8 is linked to cystic fibrosis.